AI-built bird flu shot clears animals

Scientists at the University of Cambridge say they have designed a bird flu vaccine meant to do something stockpiled flu shots generally do not: protect against many strains at once, including variants not yet circulating.

The work, published in Cell Reports Medicine and reported by Euronews, is still at the animal stage. That matters. A vaccine that performs well in mice and ferrets has not yet proved it can do the same in people, and the next step is human clinical trials.

What makes this result notable is the target. Bird flu viruses mutate quickly, and pandemic planning has largely depended on making or storing vaccines against specific strains already identified by surveillance. Cambridge researchers instead used global genetic sequence data from bird flu viruses found in wildlife, livestock and infected humans, then applied computational and evolutionary algorithms to build five synthetic antigens intended to represent that wider diversity.

In the study, the vaccine completely protected mice and ferrets exposed to several genetically distinct bird flu variants that have infected humans and are considered potential pandemic threats, according to Euronews. The same report says only half of the animals survived exposure to those viruses after receiving the World Health Organization’s existing candidate bird flu vaccine.

That is a striking comparison, but it is still a comparison inside a controlled preclinical study. It does not tell governments that current stockpiles are obsolete, and it does not tell patients anything about personal protection. It tells public health planners something more limited and still important: a broader vaccine may be technically possible.

Jonathan Heeney, who led the work at Cambridge’s Lab of Viral Zoonotics, described the approach as one that tries to anticipate viral evolution rather than chase it after the fact. For viruses such as influenza, that is the whole difficulty. The strain you prepare for can drift, and the lag between detection, manufacturing and deployment is where people are left exposed.

Euronews reports that the vaccine was developed by Cambridge and DIOSynVax Ltd, and that the team wants to take the platform into human trials and adapt it for seasonal influenza and other rapidly changing RNA viruses. For now, the established finding is narrower and sufficient on its own: a broad-spectrum bird flu vaccine has reached a published animal study.